There is still a place for significance testing in clinical trials by Cook, J, Fergusson, D, Ford, I, Gonen, M, Kimmelman, J, Korn, E, Begg, C

The fungal metabolite chaetocin is a sensitizer for pro-apoptotic therapies in glioblastoma by Ozyerli-Goknar, E, Sur-Erdem, I, Seker, F, Cingöz, A, Kayabolen, A, Kahya, Z, Uyulur, F, Gezen, M, Tolay, N, Erman, B, Gönen, M, Dunford, J, Oppermann, U, Bagci-Onder, T

Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival by Ozyerli-Goknar, E, Kala, EY, Aksu, AC, Bulut, I, Cingöz, A, Nizamuddin, S, Biniossek, M, Seker-Polat, F, Morova, T, Aztekin, C, Kung, SHY, Syed, H, Tuncbag, N, Gönen, M, Philpott, M, Cribbs, AP, Acilan, C, Lack, NA, Onder, TT, Timmers, HTM, Bagci-Onder, T

Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. by Klimstra, D, Modlin, I, Adsay, N, Chetty, R, Deshpande, V, Gönen, M, Jensen, RT, Kidd, M, Kulke, M, Lloyd, R, Moran, C, Moss, S, Oberg, K, O'Toole, D, Rindi, G, Robert, M, Suster, S, Tang, L, Tzen, C, Washington, M, Wiedenmann, B, Yao, J

PGBD5 promotes site-specific oncogenic mutations in human tumors by Henssen, A, Koche, R, Zhuang, J, Jiang, E, Reed, C, Eisenberg, A, Still, E, MacArthur, I, Rodríguez-Fos, E, Gonzalez, S, Puiggròs, M, Blackford, A, Mason, C, de Stanchina, E, Gönen, M, Emde, A, Shah, M, Arora, K, Reeves, C, Socci, N, Perlman, E, Antonescu, C, Roberts, C, Steen, H, Mullen, E, Jackson, S, Torrents, D, Weng, Z, Armstrong, S, Kentsis, A